Online Extras

Executives from Edgerton Data Consulting and MedSurgPI discuss biopharmaceutical and medical device companies outsourcing one or more aspects of their clinical trials.

Executives from Atlantic Research Group discuss the importance of CRAs in rare disease clinical trials.

This article discusses atrial fibrillation (Afib) detection and ECG recordings of the arrhythmia.

This article discusses the importance of good patient preparation, lead hook-up, and the quality checks that can be performed to ascertain that an ECG is of good quality.

Updated employee announcements, business news, awards and recognition in the industry today.

Amit Vasanji, PhD and Brett A Hoover from ERT discuss technology and the steps to successful clinical trials.

Updated employee announcements, business news, awards and recognition in the industry today.

Examining the privacy of data and the mosaic effect in healthcare.

Interest in improved project management practices is growing in the fast-moving pharma industry.

Takeda’s Atul Mahableshwarkar offers insight into central nervous system drug development and how biomarkers can improve therapy development of this discipline.

Approaches such as machine learning, AI and neural networks are still in their infancy, but with AI companies rewriting the code for drug discovery, the implications in pharma are likely to be far ranging in the coming years.

With the availability of workflow-based study start-up tools, proactive planning is within reach for stakeholders who view this function as pivotal to improving clinical trial quality.

Updated employee announcements, business news, awards and recognition in the industry today.

Functional service provisions can provide sponsors and CROs with a way to efficiently manage clinical trial outsourcing methods.

Clinical trial data from completed trials are now beginning to be shared through a variety of channels. While skeptics remain, evidence is growing that this data can lead to practice-changing behavior in patient care.

Dr. George Atiee shares his perspectives, from that of the principal investigator, on how stakeholders can execute a successful study.

The ability to carry out clinical trial visits in a patient’s home, workplace or location of choice is still an uncommon concept. However, mobile trained research nurses can expand on this idea by conducting ‘off-site’ study visits.

Initial findings from a DIA study of patient-centric initiatives in drug development reveal pharma’s desire to move toward true patient-centricity, but approaches to implementation are varied.

Updated employee announcements, business news, awards and recognition in the industry today.

Why taking a right-sized approach to real-world studies will help keep sites and patients around for the duration.

In today’s value-driven healthcare system, real-world studies are increasingly becoming mandated by regulators as a condition of approval for new medicines.

The pharma industry agrees that the importance of entering data into an EDC as soon as possible following a subject is paramount. Slow site data entry can impact the credibility and usefulness of centralized monitoring data analytic reports.

The pharma industry agrees that the importance of entering data into an EDC as soon as possible following a subject is paramount. Slow site data entry can impact the credibility and usefulness of centralized monitoring data analytic reports.

In Case Report Forms data regarding Concomitant Medication, therapies can be presented in multiple ways. Medical coding is a common task that can ensure the consistency of the captured data.

We previously covered the challenges that biopharmaceutical enterprises are facing when it comes to developing CNS medical products at ExL’s 2nd CNS Clinical Trial Forum. In this interview, Glenn Morrison, Executive Director of Clinical Development at Zogenix, will discuss how biopharmaceutical enterprises can apply techniques used in oncology clinical trials in CNS development.

Updated employee announcements, business news, awards and recognition in the industry today.

The expanding role of incentives is a healthy trend in an industry defined by high costs and the pressure of deadlines, and such agreements have evolved recently to benefit all involved.

The economics and power of the cloud will drive its increasing adoption by pharma organizations for the foreseeable future as research becomes more data-intensive.

Logistics can have a direct and measurable scientific impact on development, clinical performance and commercialization success of advanced drug therapeutics.

Justin Stark, Head and Director of Risk-based Monitoring and Standards are UCB discusses advancements in RBM and TransCelerate’s Quantitative Metrics Toolkit.